期刊文献+

高效液相色谱荧光检测法测定人血浆中溴酸加兰他敏浓度 被引量:6

Determination of Galanthamine in Plasma by High-performance Liquid Chromotography with Fluorescent Detection
下载PDF
导出
摘要 目的:建立高效液相色谱荧光法测定人血浆中氢澳酸加兰他敏浓度的方法。方法:采用hypersil-C8色谱柱,以乙腈:水:三乙胺(25:74:l)作为流动相(PH=7.0)。碱化血浆后经无水乙醚提取,挥干乙醚后,残渣经溶有参照标准品舒必利的流动相溶解后进行测定。荧光检测的激发波长为290NM,发射波长为320nm。结果:本法测定氢溴酸加兰他敏的线性范围为5~250μg.L-1(r=0.999),最低检测限1ng,最低检测浓度为5μg.L-1。日内变异系数为8.92%,日间变异系数为8.79%,萃取回收率和方法回收率均>90%。结论:本方法精密、准确、稳定,适用于加兰他敏的临床检测和药代动力学研究。 OBJECTIVE: To establishe the valid detection method with the high- performance liquid chromatography with fluorescent detection for the determination of concentration of galanthaniine in human plasma. METHODS: sulpiride was used as the reference compound. The extracts of samples were chromatographed on a hypersil C8 reversed-phase column after one-step liquid-liquid extraction by Diethyl ether absolute and monitered by fluorescence-detection and the EX290 and EM320nm. The mobile phase consists of acetonitrile: 20: triethylamine(25:74:1, pH=7.7) at a flow -rate of lml.min^(-1) RESULTS: The calibration curve was linear over the range of 5~25Oμg.L^(-1)(r=0.999). The intra-day RSD was less than 8.92%, and the inter-day was less than 8.79% . The recovery was more than 90% and the limit of quantificaiton was 5μg.L^(-1)CONCLUSION: The method has good selevtivity, sensitivity and reproducibility and has be proved to be suitable for pharmacokinetic studies of galanthamine in humans, and the clinical monitoring the plasma level of drug.
出处 《中国临床药理学杂志》 CAS CSCD 北大核心 2002年第1期66-69,共4页 The Chinese Journal of Clinical Pharmacology
关键词 高效液相色谱荧光检测法 加兰他敏 血药浓度 high-performance liquid chromotography with fluorescent detection, galanthamine, plasma concentration
  • 相关文献

参考文献6

  • 1[1]Tahomsen T, Bickel U, Fischer JP et al. Stereoselectivity of cholinesterase inhibition by galanthamine and tolerance in humans.Eur J Clin Pharmacol, 1990;39: 603~605.
  • 2[2]Tahomsen T, Bickel U, Fischer JP et al. Galanthamine hydrobromide in a long4erm treatment of Alzheimer's disease. Dementia, 1990;1: 46~51.
  • 3[3]Hermann A, Mucke. Preclinical Studies with Galanthamine. Drugs of Today, 1997;33:259~264.
  • 4[4]Westra P, Van Thiel MJS, Vermeer G.A. et al. Pharmacokinetics of galanthamine in anaesthetized patients. Br J. Anaesth, 1986;58:1303~1307.
  • 5[5]Bickel U, Thomsen T, Weber W. et al. Pharmacokinetics of galanthamine in humans and corresponding cholinesterase inhibition. Clin Pharmacol Ther, 1991;50:420~428.
  • 6[6]Mihailova D, Yamboliev I, Ahivkova Z. et al. Pharmacokinetics of galanthamine hydrobromide after single subcutaneous and oral dosage in humans. Pharmacology, 1989;39:50~58.

同被引文献49

引证文献6

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部